European Medicines Agency Hacked... Celltrion "Possible Leak of COVID-19 Treatment Documents"

EMA Notifies Unauthorized Access to Regdanvimab Documents in Recent Cyberattack

[Asia Economy Reporter Kim Ji-hee] Recently, a cyberattack on the European Medicines Agency (EMA) has resulted in unauthorized access to documents related to Celltrion's COVID-19 treatment, "Rekkironaju," among others.

On the 22nd, Celltrion announced on its website, "We have been notified by the EMA that their computer system was recently subjected to a cyberattack, and some documents related to Rekkironaju, Herzuma, and Truxima that we submitted to the EMA were accessed illegally." It is reported that not only Celltrion but also some multinational companies such as Moderna in the United States and BioNTech in Germany suffered similar damages from this cyberattack. Celltrion stated, "We believe that this cyberattack was not specifically targeted at our company."

They added, "Although there is a possibility that some of the documents we submitted to the EMA were leaked externally due to this incident, these documents did not contain any personal information of patients. We continuously monitor Celltrion's own IT systems and have confirmed that there has been no leakage or damage so far."

Currently, Celltrion is in preliminary consultations with the EMA for the marketing authorization application of Rekkironaju.

Meanwhile, the EMA previously announced on the 9th of last month (local time) that a cyberattack had occurred and that investigative authorities are currently conducting an investigation.